Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm

Joshua F. Zeidner, MD, Daniel J. Lee, MD, Gil Fine, PhD, Eunice S. Wang, MD, Vijaya R. Bhatt, MD, Andrew Dalovisio, MD, Pau Montesinos, MD PhD, Kathryn S. Kolibaba, MD, Stephen P. Anthony, DO, David J. Bearss, PhD, B. Douglas Smith, MD

Blood (2020) 136 (Supplement 1): 48–50.

https://doi.org/10.1182/blood-2020-133796

Published: 2020

Journal Articles

Β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance

Sutapa Sinha, PhD, Charla R Secreto, Justin C. Boysen, Steven L. Warner, PhD, David J. Bearss, PhD, Asish K Ghosh, PhD, Neil E. Kay, MD

Blood (2019) 134 (Supplement_1): 1739.

https://doi.org/10.1182/blood-2019-121772

Published: 2019

Journal Articles

The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma

Ethika Tyagi, PhD, Clifford Whatcott, PhD, Jason M Foulks, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2018) 132 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2018-99-120047

Published: 2018

Journal Articles

The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an MCL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination

Wontak Kim, Clifford Whatcott, PhD, Adam Siddiqui-Jain, PhD, Stephen Anthony, DO, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2018) 132 (Supplement 1): 4355.

https://doi.org/10.1182/blood-2018-99-119793

Published: 2018

Journal Articles

Enhanced Expression of Beta-Catenin and Axl Receptor Tyrosine Kinase (RTK) in Chronic Lymphocytic Leukemia (CLL) B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Leukemic Cell Drug Resistance

Sutapa Sinha, PhD, Charla R Secreto, Justin C. Boysen, Steven L. Warner, PhD, David J. Bearss, PhD, Asish K Ghosh, PhD, Neil E. Kay, MD

Blood (2018) 132 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2018-99-110981

Published: 2018

Journal Articles

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Tara L Lin, MD, Carlos E Vigil, MD, Andrew Dalovisio, MD, Eunice S. Wang, MD, Moshe Yair Levy, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD, Pau Montesinos, MD PhD, Juan Miguel Miguel Bergua Burgues, Jeffrey R. Schriber, MD, Stephen Anthony, DO, David J. Bearss, PhD, B. Douglas Smith, MD

Blood (2018) 132 (Supplement 1): 30.

https://doi.org/10.1182/blood-2018-99-115018

Published: 2018

Journal Articles

TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency

Peter Peterson, PhD, W K, Clifford Whatcott, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MD PhD, Mark Kieran, MD PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2017) 130 (Supplement 1): 937.

https://doi.org/10.1182/blood.V130.Suppl_1.937.937

Published: 2017

Journal Articles

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

Clifford J. Whatcott, PhD, James M Bogenberger, PhD, Wontak Kim, Hillary Haws, Nanna Hansen, M.S., Devora Delman, B.S., Lisa Sproat, MD MSW, Jeanne Palmer, MD, Ruben A. Mesa, MD, Peter Peterson, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MD PhD, David J. Bearss, PhD, Steven L. Warner, PhD, Raoul Tibes, MD PhD

Blood (2016) 128 (22): 1652.

https://doi.org/10.1182/blood.V128.22.1652.1652

Published: 2016

Journal Articles

The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease

Peter Peterson, PhD, Wontak Kim, Hillary Haws, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2016) 128 (22): 263.

https://doi.org/10.1182/blood.V128.22.263.263

Published: 2016

Journal Articles

Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase

Sutapa Sinha, PhD, Justin C Boysen, Kari G. Chaffee, MS, Brian F Kabat, Susan L. Slager, PhD, Sameer A. Parikh, MD, Charla R Secreto, Tait D. Shanafelt, MD, Jose F. Leis, MD PhD, Steven L. Warner, PhD, David J. Bearss, PhD, Asish K Ghosh, PhD, Neil E. Kay, MD

Blood (2016) 128 (22): 2020.

https://doi.org/10.1182/blood.V128.22.2020.2020

Published: 2016

Journal Articles

ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease

Peter Peterson, PhD, Katherine K. Soh, Ye Sol Lee, Wontak Kim, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 273.

https://doi.org/10.1182/blood.V126.23.273.273

Published: 2015

Journal Articles

Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion

Wontak Kim, Katherine K. Soh, Jeremiah J. Bearss, Ye Sol Lee, Peter Peterson, PhD, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MDPhD, James M Bogenberger, PhD, Raoul Tibes, MD PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 1343.

https://doi.org/10.1182/blood.V126.23.1343.1343

Published: 2015

Journal Articles

Inhibition of Axl Kinase Reverses the Mesenchymal Phenotype in Leukemic Cells through the Disruption of Retinoic Acid Signaling

Katherine K. Soh, Brigham L. Bahr, Jeremiah J. Bearss, Wontak Kim, Peter Peterson, PhD, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 3253.

https://doi.org/10.1182/blood.V126.23.3253.3253

Published: 2015

Journal Articles

Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML

Wontak Kim, Brigham L. Bahr, Katherine K. Soh, Jeremiah J. Bearss, Ye Sol Lee, Peter Peterson, PhD, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MDPhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 3799.

https://doi.org/10.1182/blood.V126.23.3799.3799

Published: 2015

Journal Articles

Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton Tyrosine Kinase Inhibitors

Sutapa Sinha, PhD, Justin Boysen, Michael Nelson, Charla Secreto, Steven L. Warner, PhD, David J. Bearss, PhD, Connie Lesnick, M.Sc, Tait D. Shanafelt, MD, Neil E. Kay, MD, Asish K Ghosh, PhD

Blood (2014) 124 (21): 1946.

https://doi.org/10.1182/blood.V124.21.1946.1946

Published: 2014

Journal Articles

The Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted Therapy in Acute Myeloid Leukemia

Il-Kyoo Park, PhD, Bethany Mundy-Bosse, PhD, Steven L. Warner, PhD, David J. Bearss, PhD, Guido Marcucci, MD, Michael A. Caligiuri, MD

Blood (2014) 124 (21): 2350.

https://doi.org/10.1182/blood.V124.21.2350.2350

Published: 2014

Journal Articles

Novel Series of ALK2 Inhibitors That Alter Hepcidin Expression As Potential Therapeutics for Anemia of Chronic Disease

Wontak Kim, Kyle S. Maughan, Katherine K. Soh, Jeremiah J. Bearss, Brigham L. Bahr, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2014) 124 (21): 212.

https://doi.org/10.1182/blood.V124.21.212.212

Published: 2014

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

Warren Fiskus, Ph.D., Sunil Sharma, M.D., Sunil Abhyankar, MD, Joseph McGuirk, DO, David J. Bearss, PhD, Kapil Bhalla, MD

Blood (2012) 120 (21): 868.

https://doi.org/10.1182/blood.V120.21.868.868

Published: 2012

Journal Articles

Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells

Warren Fiskus, PhD, Sunil Sharma, MD, Rekha Rao, PhD, Ramesh Balusu, PhD, Sreedhar Venkannagari, PhD, Stacey Hembruff, MS, Siddhartha Ganguly, MD, Eduardo M. Sotomayor, Jianguo Tao, MD, PhD, David J. Bearss, PhD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 2429.

https://doi.org/10.1182/blood.V118.21.2429.2429

Published: 2011

Journal Articles

Pim Kinase Inhibitor, SGI-1776, Induces Apoptosis in CLL Lymphocytes

Lisa S Chen, Ph.D, William G Wierda, M.D., Ph.D, Sanjeev Redkar, Ph.D, David J. Bearss, PhD, Varsha Gandhi, Ph.D

Blood (2008) 112 (11): 4199.

https://doi.org/10.1182/blood.V112.11.4199.4199

Published: 2008

NARROW

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm

Β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance

The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma

The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an MCL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination

Enhanced Expression of Beta-Catenin and Axl Receptor Tyrosine Kinase (RTK) in Chronic Lymphocytic Leukemia (CLL) B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Leukemic Cell Drug Resistance

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease

Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase

ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease

Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion

Inhibition of Axl Kinase Reverses the Mesenchymal Phenotype in Leukemic Cells through the Disruption of Retinoic Acid Signaling

Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML

Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton Tyrosine Kinase Inhibitors

The Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted Therapy in Acute Myeloid Leukemia

Novel Series of ALK2 Inhibitors That Alter Hepcidin Expression As Potential Therapeutics for Anemia of Chronic Disease

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells

Pim Kinase Inhibitor, SGI-1776, Induces Apoptosis in CLL Lymphocytes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only